Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12134062 | 0.84 | IDO1 (0.61) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL23091915 | 0.83 | IDO1 (0.66) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL8062311 | 0.83 | IDO1 (0.70) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL37463 | 0.83 | IDO1 (0.70) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL28621039 | 0.82 | CA12 (0.76) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL7032223 | 0.80 | IDO1 (0.61) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL7769668 | 0.79 | IDO1 (0.66) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL293414 | 0.79 | IDO1 (0.66) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL21753899 | 0.79 | IDO1 (0.66) | IDO1AKR1C3LOXL2CA12CA1 | |
| SCHEMBL7829129 | 0.79 | IDO1 (0.66) | IDO1AKR1C3LOXL2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104341316-A | Diarylamide type derivatives, preparing method thereof, pharmaceutical compositions of the derivatives and uses of the derivatives | SHANGHAI INST MATERIA MEDICA | 2015-02-11 | — | — | CN | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| EP-2044081-A2 | IMPROVED OXIDATION PROCESS WITH ENHANCED SAFETY USEFUL IN THE MANUFACTURE OF MOXIDECTIN BY MEANS OF STABILISED 2-IODOXYBENZOIC ACID (SIBX) | Wyeth (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007149305-A2 | IMPROVED OXIDATION PROCESS WITH ENHANCED SAFETY USEFUL IN THE MANUFACTURE OF MOXIDECTIN BY MEANS OF STABILISED 2-IODOXYBENZOIC ACID (SIBX) | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
| CN-1914151-A | Nitric oxide releasing prodrugs of diaryl-2 (5H) -furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA INC (CA) | 2007-02-14 | — | — | CN | disclosed |
| US-4992542-A | Thienamycin antibiotics | MERCK & CO., INC. (US) | 1991-02-12 | — | — | US | disclosed |
| EP-0313474-A2 | An optical article exhibiting a high level of second order polarization susceptibility | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4180383-A | Chamber holder for immobilized immunoadsorbent | BECTON, DICKINSON AND COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4051186-A | AMINO-PROPRANOLOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | IDO1 3213/4885AKR1C3 4450/4885LOXL2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.